Monday, February 23, 2026

AOP Health on Rare Diseases: Information. Collaboration. Innovation.

 


VIENNA 

Why closing knowledge gaps matters for patients, healthcare and innovation.


(BUSINESS WIRE)--Between 27 and 36 million1 people in Europe are living with a rare disease, yet only around six percent currently have access to an approved treatment2. Progress in diagnosis and treatment is often slowed by knowledge gaps, including the lack of clear, reliable, and patient-friendly information needed to support informed decision-making. Drawing on 30 years of experience in researching and developing therapies for rare diseases, AOP Health underscores the importance of collaboration across the healthcare community. On Rare Disease Day 2026, the company joins healthcare professionals, researchers and patient representatives in highlighting the need for closer cooperation to generate, share and better use scarce data to improve care for people living with rare diseases.


“Working in rare diseases since 1996 has shown us that innovation is never a solo effort,” emphasized Melissa Fellner, Vice President Global Therapeutic Areas at AOP Health. “It requires continuous investment in data, open collaboration and information that reaches patients in a form they can use.”


Consistent with this approach, AOP Health is conducting five clinical studies in the field of rare diseases. The company collaborates with researchers at numerous renowned international universities, as well as 58 patient organizations, most of which focus on rare diseases. These partnerships aim to leverage synergies and to strengthen the evidence base.


Collaboration is key


Prof. Dr. med. Haifa Kathrin Al-Ali, a professor of internal medicine at Halle (Saale) University Hospital and Director of the Krukenberg Cancer Center Halle, shares AOP Health’s perspectives. " Without informed patients, it is difficult to generate evidence that truly represents daily clinical reality," she said. "Close collaboration and an exchange on equal footing are therefore essential, especially in rare diseases.”


Thus, cooperation between physicians, patients and the pharmaceutical industry plays a crucial role in advancing research.


New EU regulations require informed patients


Furthermore, patient involvement is becoming increasingly central to European evaluation and decision-making processes. New frameworks, such as joint clinical assessments (JCAs), and structured evaluation approaches, such as PICO (which defines populations, comparators, and patient-relevant outcomes), explicitly rely on evidence that reflects real-world needs and experiences. Therefore, robust, patient-relevant data and informed patient perspectives are becoming increasingly critical.


However, meaningful patient participation in these processes requires access to appropriate knowledge and competencies. Eva Otter, Vice President of PHA Europe, a patient advocacy group representing people living with pulmonary hypertension globally emphasizes, "To meet European requirements and participate effectively in evaluation processes, we need access to reliable, evidence-based information presented in a language we can understand. Patient-friendly expert information is therefore not an add-on, but a prerequisite for informed participation and credible assessments."


Rare Disease Day 2026: Extending access to patient-centred information


To coincide with Rare Disease Day 2026, AOP Health is releasing a new episode of its German-language patient podcast to support patients in processing their diagnosis. This episode focuses on health literacy and addresses a central question: How can patients become well-informed and actively engaged in their care?


Links


Take a look at aop-health.com from 26.2.-2.3.2026 for a Rare Disease Day special and listen to the podcast „Ab jetzt ist alles anders? Leben nach und mit einer schwerwiegenden Diagnose“. (“Everything's Different Now? Life After and With a Serious Diagnosis") here.


About AOP Health


AOP Health is a global enterprise group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. The group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim "Needs. Science. Trust." the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the company’s actions. (aop-health.com)


1 https://health.ec.europa.eu/european-reference-networks/rare-diseases_en

2 https://www.eurordis.org/rare-disease-policy/european-policy/


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260223167500/en/



Permalink

https://www.aetoswire.com/en/news/54429786


Contacts

 

Further inquiry

DI Isolde Fally

Isolde.Fally@aop-health.com

https://www.aop-health.com

Axelspace Secures Japan Ministry of Defense Satellite Constellation Project

 As an optical imagery provider, Axelspace has entered into a contract for the acquisition of image data


(BUSINESS WIRE) -- Axelspace Corporation (“Axelspace”), a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” announced that, for the purpose of carrying out the Ministry of Defense’s satellite constellation project, it has entered into a contract with Tri-Sat Constellation Co., Ltd. and Mitsui Bussan Aerospace Co., Ltd. for acquisition of optical imagery data. Tri-Sat Constellation Co., Ltd. is a special purpose company (SPC) established by Mitsubishi Electric Corporation, SKY Perfect JSAT Corporation, and Mitsui & Co., Ltd.


The Ministry of Defense’s satellite constellation project was awarded to a consortium comprising Mitsubishi Electric Corporation, SKY Perfect JSAT Corporation, Mitsui & Co., Ltd., Synspective Inc., Institute for Q-shu Pioneers of Space, Inc., Mitsui Bussan Aerospace Co., Ltd., and Axelspace. Tri-Sat Constellation Co., Ltd. signed the project with the Ministry of Defense for the project on February 19. Axelspace, as the sole provider of optical imagery among the partner companies, will contribute by satellite imagery acquisition to the project.


This project is a Private Finance Initiative (PFI) project aimed at building a satellite constellation operated by private-sector companies to ensure stable acquisition of imagery intelligence necessary for ensuring the effectiveness of stand-off defense capabilities*.


* Stand-off defense capabilities are the ability to effectively counter external attacks from a distant position outside the threat range.


“Under the recently concluded contract, Axelspace will participate as the sole optical imagery provider,” said Yuya Nakamura, President and CEO of Axelspace Corporation. “Based on the satellite development and operation technologies we have built to date, as well as our track record of stable image data provision, we aim to accurately address the needs of the national security field. At the same time, we will continue to actively expand the utilization of satellite data in the private sector and emerging markets, which are expected to see significant growth in the future.”


For the full press release, please visit: https://www.axelspace.com/news/satellite_constellation_project/


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260220758297/en/



Permalink

https://www.aetoswire.com/en/news/2002202653464


Contacts

Media Contact

Axelspace Holdings Corporation

pr@axelspace.com

Sunday, February 22, 2026

Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results


 LAS VEGAS -

Fourth Quarter and Full Year 2025 Financial Highlights Include:


Remaining Performance Obligations (RPO) of $652.9 million, up 11.1% from the prior year


Adjusted Calculated Billings, full year 2025, up 4.2% from the prior year


Adjusted Annualized Recurring Revenue (ARR) up 3.1% from the prior year


 


(BUSINESS WIRE)--Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the 2025 fourth quarter and fiscal year ended December 31, 2025.


“Our fourth quarter results reflect solid execution and continued accelerating sales growth, adjusted for the Oracle PeopleSoft support and services wind down. We grew our core Rimini Support™ subscription billings and launched our next generation Agentic AI ERP solutions that can be easily and quickly deployed over the top of existing ERP Software without the cost or risk of unnecessary ERP Software upgrades, migrations or replatforming,” said Seth Ravin, president and CEO, Rimini Street. “ERP Software is peaking technically, and we will deliver new ERP capabilities and ERP Process execution faster, better and cheaper with more agility and speed to market leveraging Rimini Street’s Agentic AI ERP solutions. Meanwhile, we will keep existing ERP Software and releases delivering value for many years to come at significant savings.”


“Our fourth quarter results exceeded the guidance range we communicated at our Investor Day and demonstrate continued positive momentum entering 2026,” said Michael Perica, CFO, Rimini Street. “We invested in the development and launch of new AI-based solutions, streamlined global operations, achieved new RPO records in both the third and fourth quarters with increased year over year and sequential growth, increased our net cash year over year and ended fiscal year 2025 with a strong balance sheet and cash position. Capital allocation actions during the year included share repurchases and full repayment of the revolving line of credit.”


Select Fourth Quarter 2025 Financial Results


Revenue was $109.8 million for the fourth quarter of 2025, a decrease of 3.9% compared to $114.2 million for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, revenue decreased by 0.4%.

U.S. revenue was $47.5 million for the fourth quarter of 2025, a decrease of 10.6% compared to $53.1 million for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, U.S. revenue decreased by 4.3%.

International revenue was $62.3 million for the fourth quarter of 2025, an increase of 2.0% compared to $61.1 million for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, international revenue increased by 2.6%.

Subscription revenue was $104.9 million, which accounted for 95.6% of total revenue for the fourth quarter of 2025, compared to subscription revenue of $109.1 million, which accounted for 95.5% of total revenue for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, subscription revenue was $101.0 million, or 95.5% of total revenue, for the fourth quarter of 2025 compared to $101.4 million, or 95.5% of total revenue, for the same period last year.

Annualized Recurring Revenue was $411.4 million for the fourth quarter of 2025, a decrease of 0.8% compared to $414.8 million for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, Adjusted Annualized Recurring Revenue was $395.8 million for the fourth quarter of 2025, an increase of 3.1% compared to $384.0 million for the same period last year.

Active Clients as of December 31, 2025 were 3,102, an increase of 0.7% compared to 3,081 Active Clients as of December 31, 2024.

Revenue Retention Rate was 88% and 88% for the trailing 12 months ended December 31, 2025 and 2024, respectively.

Calculated Billings was $171.3 million for the fourth quarter of 2025, a decrease of 0.4% compared to $172.1 million for the same period last year.

Adjusted Calculated Billings, which excludes Calculated Billings related to the support services for Oracle’s PeopleSoft software products, was $167.3 million for the fourth quarter of 2025, an increase of 0.7% compared to $166.2 million for the same period last year.

Remaining Performance Obligations (RPO) was a record $652.9 million as of December 31, 2025, an increase of 11.1% compared to $587.9 million as of December 31, 2024; excluding the support services for Oracle’s PeopleSoft software products, Adjusted RPO was $632.2 million as of December 31, 2025, an increase of 11.7% compared to $565.9 million as of December 31, 2024.

Gross margin was 60.4% for the fourth quarter of 2025 compared to 63.7% for the same period last year.

Operating income was $5.0 million for the fourth quarter of 2025 compared to an operating income of $14.9 million for the same period last year.

Non-GAAP Operating Income was $10.3 million for the fourth quarter of 2025 compared to $19.1 million for the same period last year.

Net income was $0.7 million for the fourth quarter of 2025 compared to $6.7 million for the same period last year.

Non-GAAP Net Income was $6.0 million for the fourth quarter of 2025 compared to $10.8 million for the same period last year.

Adjusted EBITDA for the fourth quarter of 2025 was $11.5 million compared to $20.0 million for the same period last year.

Both the basic and diluted earnings per share attributable to common stockholders were $0.01 for the fourth quarter of 2025, compared to a basic and diluted earnings per share of $0.07 for the same period last year.

Cash and cash equivalents were $120.0 million at December 31, 2025 compared to $88.8 million at December 31, 2024.

Repurchased approximately 1.0 million shares of Common Stock for approximately $3.8 million at an average price of $3.92 per share during the fourth quarter of 2025.

Select Full Year 2025 Financial Results


Revenue was $421.5 million for 2025, a decrease of 1.7% compared to $428.8 million for 2024; excluding the support services for Oracle’s PeopleSoft software products, revenue increased by 1.0%.

Calculated Billings was $427.9 million for 2025, an increase of 1.2% compared to $423.0 million for the same period last year.

Adjusted Calculated Billings, which excludes Calculated Billings related to the support services for Oracle’s PeopleSoft software products, was $414.2 million for 2025, an increase of 4.2% compared to $397.4 million for the same period last year.

Gross margin was 60.4% for 2025 compared to 60.9% for 2024.

Operating income was $59.9 million for 2025 compared to an operating loss of $32.1 million for 2024.

Non-GAAP Operating Income was $44.1 million for 2025 compared to $47.7 million for 2024.

Net income was $37.1 million for 2025 compared to a net loss of $36.3 million for 2024.

Non-GAAP Net Income was $21.3 million for 2025 compared to $43.6 million for 2024.

Adjusted EBITDA was $49.8 million for 2025 compared to $53.1 million for 2024.

Basic and diluted net earnings per share attributable to common stockholders were $0.40 and $0.39, respectively, for 2025, compared to a basic and diluted net loss per share of $(0.40) and $(0.40), respectively, for 2024.

Repurchased approximately 1.9 million shares of Common Stock for approximately $7.6 million at an average price of $4.07 per share during 2025.

Select Fourth Quarter 2025 Operating Results


Announced new and existing clients that expanded their agreements with Rimini Street, including the following:

Ypê, a leading Brazilian consumer goods company and a Rimini Street SAP S/4HANA support client, is accelerating its Agentic AI initiatives through the adoption of Rimini Street’s Agentic UX platform.

Tidewater, the world’s largest offshore service vessel operator, expanded its partnership with Rimini Street by adding Rimini Connect™ and Rimini Consult™ to address critical interoperability challenges.

Silicon Labs, a leading U.S.-based provider of semiconductor solutions, software, and IoT technologies, expanded its partnership with Rimini Street through a new five‑year agreement. The engagement includes support for its SAP ECC 6.0 environment and leverages Rimini Consult™ services to advance modernization initiatives including Agentic AI–driven ERP innovation solutions.

SP Electricity North West eliminated recurring SAP issues, cut maintenance costs by 50% and boosted service‑desk efficiency by 10% after implementing Rimini Street’s ERP support and single sign‑on optimization solution.

Unveiled groundbreaking “Agentic AI ERP” vision in a new white paper, declaring traditional ERP software obsolete and introducing a next‑generation, AI‑driven architecture that delivers faster, more agile, lower‑cost innovation—deployed over existing ERP systems with no required upgrades.

Launched 20 new Rimini Agentic UX™ Solutions, Powered by ServiceNow®, delivering rapid, AI‑driven ERP process automation that improves productivity, reduces costs and deploys in days or weeks—without requiring ERP upgrades, migrations or replatforming.

Announced that thousands of organizations now rely on the Rimini Smart Path™—a three‑step Support, Optimize, and Innovate methodology—to free budget, reduce operational burden, and accelerate AI‑driven innovation without costly ERP upgrades or migrations.

Received multiple industry honors recognizing its AI innovation, technical excellence and client‑first culture, including the Tech Ascension Award for AI‑Powered Enterprise (Agent) Solution of the Year, the Top Tech of the Year Award in Las Vegas honoring CEO Seth Ravin, the Silver Globee Award for Customer Service Team of the Year, and recognition for client Hitachi Vantara’s Gauri Kapur, winner of the 2025 Women Leading IT Award.

Announced a new global survey of nearly 4,300 C‑suite leaders, which revealed intensifying pressure to deliver AI‑driven innovation, stronger ROI and greater business resilience as executives navigate rising costs, increasing risk, persistent IT talent shortages, and frustration with vendor‑driven ERP roadmaps.

Announced a new global survey that finds Oracle Database customers are shifting strategies due to high costs, support challenges and growing demand for advanced AI/ML capabilities, with many turning to third‑party support to reduce fees, improve responsiveness, and unlock resources for innovation.

Announced global study of 455 SAP customers that finds strong shift toward multi‑vendor composable ERP, with organizations using third‑party support achieving above‑average performance 83% of the time versus 27% with traditional SAP‑led approaches.

Hosted an Investor Day on December 3, 2025 with videos and presentations posted and available for viewing on the Rimini Street Investor Relations website for one year.

Resolved more than 7,100 support cases and delivered over 10,800 tax, legal, and regulatory updates across 32 countries, achieving an average client satisfaction score above 4.9 out of 5.0 (where 5.0 is rated excellent).

Business Outlook


The Company is providing first quarter 2026 revenue guidance to be in the range of $101.5 million to $103.5 million and reiterating full year 2026 guidance as communicated at the Company’s Investor Day for revenue growth in the 4% to 6% range with Adjusted EBITDA margins in the 12.5% to 15.5% range.


Webcast and Conference Call Information


Rimini Street will host a conference call and webcast to discuss the fourth quarter and full year 2025 results and offer commentary on 2026 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on February 19, 2026. A live webcast of the event will be available on Rimini Street’s Investor Relations site at Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference call by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event.


Company’s Use of Non-GAAP Financial Measures


This press release contains certain “non-GAAP financial measures.” Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles. This non-GAAP information supplements and is not intended to represent a measure of performance in accordance with disclosures required by U.S. generally accepted accounting principles, or GAAP. Non-GAAP financial measures should be considered in addition to, and not as a substitute for or superior to, financial measures determined in accordance with GAAP.


Reconciliations of the non-GAAP financial measures included in this press release and described below to their most directly comparable GAAP financial measures are provided in the financial tables included at the end of this press release. An explanation of these measures, why we believe they are meaningful and how they are calculated is also included under the heading “About Non-GAAP Financial Measures and Certain Key Metrics.”


About Rimini Street, Inc.


Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a proven, trusted global provider of end-to-end, mission-critical enterprise software support, managed services and innovative Agentic AI ERP solutions, and is the leading third-party support provider for Oracle, SAP and VMware software. The Company has signed thousands of IT service contracts with Fortune Global 100, Fortune 500, midmarket, public sector and government organizations who have leveraged the Rimini Smart Path™ methodology to achieve better operational outcomes, billions of US dollars in savings and fund AI and other innovation.


To learn more, please visit www.riministreet.com, and connect with Rimini Street on X, Facebook, Instagram, and LinkedIn.


Forward-Looking Statements


Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “currently,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “outlook,” “plan,” “possible,” “goal,” “potential,” “predict,” “project,” “reflect,” “results,” “seem,” “seek,” “should,” “will,” “would” and other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to our ability to attract new clients or retain and/or sell additional products or services to existing clients; our ability to achieve and maintain an adequate rate of revenue growth; cost of revenue, including changes in costs associated with our efforts to grow and the results of any efforts to manage costs to align with current revenue expectations and the expansion of our offerings; the effects of increased intense competition in our industry and our ability to compete effectively; our ability to successfully educate the market regarding the advantages of our support and managed services for enterprise resource planning (ERP) software and to sell the products and services comprising our “Rimini Smart Path™” solutions portfolio, including but not limited to our Agentic AI ERP solutions; our intentions with respect to our pricing model and expectations of client savings relative to use of other providers; the evolution of the ERP software management and support landscape facing our clients and prospects; estimates of our total addressable market; the effects of seasonal trends on our results of operations, including the contract renewal cycles for vendor-supplied software support and managed services; the effects of the efforts of enterprise software vendors to sell upgrades or migrations to cloud-based versions of their enterprise software on our results of operations; our ability to scale our operations quickly enough to meet our clients’ changing needs or decrease our costs adequately in response to changing client demand; risks arising from incorporating artificial intelligence (“AI”) technologies into our products or services or any deficiencies associated with AI technologies used by us or by our third-party vendors and service providers; our ability to maintain, protect, and enhance our brand; the continuing impact of and our ability to comply with the terms of our July 2025 settlement agreement with Oracle; our wind down of support services for Oracle PeopleSoft software products and the impact on future period revenue and costs incurred related to these efforts; the loss of one or more members of our management team and our ability to attract and retain additional qualified technical, sales and marketing personnel; our ability to expand our marketing and sales capabilities; our ability to avoid interruptions to, or degraded performance of, our services and the impact of any such interruptions or performance problems on our operations; our ability to defend against cybersecurity threats and to comply with data protection and privacy regulations; our expectations regarding new product offerings, innovation solutions, partnerships and alliance programs and our ability to develop and maintain strategic partnerships; our ability to expand internationally and the risks associated with global operations; the impact of macro-economic trends, including inflation and changes in foreign exchange rates, as well as general financial, economic, regulatory and political conditions affecting the industry in which we operate and the industries in which our clients operate; our ability to generate significant capital through our operations or to raise additional capital necessary to fund and expand our operations and invest in new services and products; our business plan and our ability to effectively secure and manage our growth and associated investments; risks relating to retention rates, including our ability to accurately predict retention rates; our ability to protect our intellectual property; our ability to maintain an effective system of internal control over financial reporting; changes in laws or regulations, including tax laws or unfavorable outcomes of tax positions we take; tariff costs, including those imposed by the United States government and the potential for retaliatory trade measures by affected countries; our ability to realize benefits from our net operating losses; any negative impact of environmental, social and governance (“ESG”) matters on our reputation or business and the exposure of our business to additional costs or risks from our reporting on such matters; our credit facility’s ongoing debt service obligations and financial and operational covenants on our business and related interest rate risk; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the volatility of our stock price; the amount and timing of repurchases, if any, under our stock repurchase program and our ability to enhance stockholder value through such program; our ability to maintain our good standing with the United States government and international governments and capture new contracts with governmental entities/agencies; the occurrence of catastrophic events that may disrupt our business or that of our current and prospective clients; future acquisitions of, or investments in, complementary companies, products, subscriptions or technologies; and those discussed under the heading “Risk Factors” in Rimini Street’s Annual Report on Form 10-K filed on February 19, 2026, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the U.S. Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.


© 2026 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.


RIMINI STREET, INC.


Unaudited Condensed Consolidated Balance Sheets


(In thousands, except per share amounts)


ASSETS


December 31,

2025


 


December 31, 2024


Current assets:


 


 


 


Cash and cash equivalents


$


119,974


 


 


$


88,792


 


Restricted cash, current


 


341


 


 


 


430


 


Accounts receivable, net of allowance of $1,443 and $653, respectively


 


136,866


 


 


 


130,784


 


Deferred contract costs, current


 


17,734


 


 


 


17,076


 


Prepaid expenses and other


 


25,447


 


 


 


19,194


 


Total current assets


 


300,362


 


 


 


256,276


 


Long-term assets:


 


 


 


Restricted cash, noncurrent


 


785


 


 


 



 


Property and equipment, net of accumulated depreciation and amortization of $23,822 and $21,305, respectively


 


10,239


 


 


 


9,891


 


Operating lease right-of-use assets


 


21,371


 


 


 


7,161


 


Deferred contract costs, noncurrent


 


24,436


 


 


 


22,084


 


Deposits and other


 


8,379


 


 


 


5,068


 


Deferred income taxes, net


 


57,540


 


 


 


68,583


 


Total assets


$


423,112


 


 


$


369,063


 


LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT


Current liabilities:


 


 


 


Current maturities of long-term debt


$


4,031


 


 


$


3,093


 


Accounts payable


 


5,752


 


 


 


5,275


 


Accrued compensation, benefits and commissions


 


39,609


 


 


 


33,586


 


Other accrued liabilities


 


24,307


 


 


 


20,688


 


Operating lease liabilities, current


 


4,984


 


 


 


3,967


 


Deferred revenue, current


 


268,717


 


 


 


257,983


 


Total current liabilities


 


347,400


 


 


 


324,592


 


Long-term liabilities:


 


 


 


Long-term debt, net of current maturities


 


63,156


 


 


 


82,187


 


Deferred revenue, noncurrent


 


18,824


 


 


 


23,214


 


Operating lease liabilities, noncurrent


 


18,843


 


 


 


7,064


 


Other long-term liabilities


 


1,918


 


 


 


1,451


 


Total liabilities


 


450,141


 


 


 


438,508


 


Stockholders' deficit:


 


 


 


Preferred Stock, $0.0001 par value per share. Authorized 99,820 shares (excluding


180 shares of Series A Preferred Stock); no other series has been designated


 



 


 


 



 


Common Stock, $0.0001 par value. Authorized 1,000,000 shares; issued and outstanding 91,603 and 91,120 shares, respectively


 


9


 


 


 


9


 


Additional paid-in capital


 


181,075


 


 


 


177,533


 


Accumulated other comprehensive loss


 


(5,613


)


 


 


(7,389


)


Accumulated deficit


 


(201,384


)


 


 


(238,482


)


Treasury stock,, at cost, 137 and 137 shares, respectively


 


(1,116


)


 


 


(1,116


)


Total stockholders' deficit


 


(27,029


)


 


 


(69,445


)


Total liabilities and stockholders' deficit


$


423,112


 


 


$


369,063


 


RIMINI STREET, INC.


Unaudited Condensed Consolidated Statements of Operations


(In thousands, except per share amounts)


 


Three Months Ended


 


Year Ended


 


December 31,


 


December 31,


 


 


2025


 


 


 


2024


 


 


 


2025


 


 


 


2024


 


Revenue


$


109,790


 


 


$


114,213


 


 


$


421,536


 


 


$


428,753


 


Cost of revenue


 


43,514


 


 


 


41,501


 


 


 


166,935


 


 


 


167,731


 


Gross profit


 


66,276


 


 


 


72,712


 


 


 


254,601


 


 


 


261,022


 


Operating expenses:


 


 


 


 


 


 


 


Sales and marketing


 


41,355


 


 


 


37,437


 


 


 


151,569


 


 


 


149,736


 


General and administrative


 


17,380


 


 


 


18,624


 


 


 


69,997


 


 


 


73,084


 


Reorganization costs


 


2,555


 


 


 


1,098


 


 


 


4,491


 


 


 


5,737


 


Litigation costs and related recoveries:


 


 


 


 


 


 


 


Litigation settlement


 



 


 


 



 


 


 


(36,196


)


 


 


58,512


 


Professional fees and other costs of litigation


 


21


 


 


 


675


 


 


 


4,831


 


 


 


6,081


 


Litigation costs and related recoveries, net


 


21


 


 


 


675


 


 


 


(31,365


)


 


 


64,593


 


Total operating expenses


 


61,311


 


 


 


57,834


 


 


 


194,692


 


 


 


293,150


 


Operating income (loss)


 


4,965


 


 


 


14,878


 


 


 


59,909


 


 


 


(32,128


)


Non-operating income and (expenses):


 


 


 


 


 


 


 


Interest expense


 


(1,401


)


 


 


(1,904


)


 


 


(6,151


)


 


 


(6,305


)


Other income (expenses), net


 


187


 


 


 


(24


)


 


 


1,873


 


 


 


1,790


 


Income (loss) before income taxes


 


3,751


 


 


 


12,950


 


 


 


55,631


 


 


 


(36,643


)


Income tax benefit (expense)


 


(3,027


)


 


 


(6,291


)


 


 


(18,533


)


 


 


371


 


Net income (loss)


$


724


 


 


$


6,659


 


 


$


37,098


 


 


$


(36,272


)


 


 


 


 


 


 


 


 


Net income (loss) per share attributable to common stockholders:


 


 


 


 


 


 


 


Basic


$


0.01


 


 


$


0.07


 


 


$


0.40


 


 


$


(0.40


)


Diluted


$


0.01


 


 


$


0.07


 


 


$


0.39


 


 


$


(0.40


)


Weighted average number of shares of Common Stock outstanding:


 


 


 


 


 


 


 


Basic


 


91,395


 


 


 


90,979


 


 


 


91,736


 


 


 


90,503


 


Diluted


 


94,641


 


 


 


91,493


 


 


 


94,490


 


 


 


90,503


 


RIMINI STREET, INC.


GAAP to Non-GAAP Reconciliations


(In thousands)


 


Three Months Ended


 


Year Ended


 


December 31,


 


December 31,


 


 


2025


 


 


 


2024


 


 


 


2025


 


 


 


2024


 


Non-GAAP operating income reconciliation:


 


 


 


 


 


 


 


Operating income (loss)


$


4,965


 


 


$


14,878


 


 


$


59,909


 


 


$


(32,128


)


Non-GAAP adjustments:


 


 


 


 


 


 


 


Litigation costs and related recoveries, net


 


21


 


 


 


675


 


 


 


(31,365


)


 


 


64,593


 


Stock-based compensation expense


 


2,711


 


 


 


2,408


 


 


 


11,071


 


 


 


9,545


 


Reorganization costs


 


2,555


 


 


 


1,098


 


 


 


4,491


 


 


 


5,737


 


Non-GAAP operating income


$


10,252


 


 


$


19,059


 


 


$


44,106


 


 


$


47,747


 


Non-GAAP net income reconciliation:


 


 


 


 


 


 


 


Net income (loss)


$


724


 


 


$


6,659


 


 


$


37,098


 


 


$


(36,272


)


Non-GAAP adjustments:


 


 


 


 


 


 


 


Litigation costs and related recoveries, net


 


21


 


 


 


675


 


 


 


(31,365


)


 


 


64,593


 


Stock-based compensation expense


 


2,711


 


 


 


2,408


 


 


 


11,071


 


 


 


9,545


 


Reorganization costs


 


2,555


 


 


 


1,098


 


 


 


4,491


 


 


 


5,737


 


Non-GAAP net income


$


6,011


 


 


$


10,840


 


 


$


21,295


 


 


$


43,603


 


Non-GAAP Adjusted EBITDA reconciliation:


 


 


 


 


 


 


 


Net income (loss)


$


724


 


 


$


6,659


 


 


$


37,098


 


 


$


(36,272


)


Non-GAAP adjustments:


 


 


 


 


 


 


 


Interest expense


 


1,401


 


 


 


1,904


 


 


 


6,151


 


 


 


6,305


 


Income taxes


 


3,027


 


 


 


6,291


 


 


 


18,533


 


 


 


(371


)


Depreciation and amortization expense


 


1,022


 


 


 


947


 


 


 


3,861


 


 


 


3,596


 


EBITDA


 


6,174


 


 


 


15,801


 


 


 


65,643


 


 


 


(26,742


)


Non-GAAP adjustments:


 


 


 


 


 


 


 


Litigation costs and related recoveries, net


 


21


 


 


 


675


 


 


 


(31,365


)


 


 


64,593


 


Stock-based compensation expense


 


2,711


 


 


 


2,408


 


 


 


11,071


 


 


 


9,545


 


Reorganization costs


 


2,555


 


 


 


1,098


 


 


 


4,491


 


 


 


5,737


 


Adjusted EBITDA


$


11,461


 


 


$


19,982


 


 


$


49,840


 


 


$


53,133


 


Calculated Billings:


 


 


 


 


 


 


 


Revenue


$


109,790


 


 


$


114,213


 


 


$


421,536


 


 


$


428,753


 


Deferred revenue, current and noncurrent, end of the period


 


287,541


 


 


 


281,197


 


 


 


287,541


 


 


 


281,197


 


Deferred revenue, current and noncurrent, beginning of the period


 


225,999


 


 


 


223,314


 


 


 


281,197


 


 


 


286,974


 


Change in deferred revenue


 


61,542


 


 


 


57,883


 


 


 


6,344


 


 


 


(5,777


)


Calculated billings


 


171,332


 


 


 


172,096


 


 


 


427,880


 


 


 


422,976


 


Less PeopleSoft calculated billings


 


(4,039


)


 


 


(5,918


)


 


 


(13,728


)


 


 


(25,619


)


Adjusted calculated billings


$


167,293


 


 


$


166,178


 


 


$


414,152


 


 


$


397,357


 


RIMINI STREET, INC.


GAAP to Non-GAAP Reconciliations


(In thousands)


 


 


Three Months Ended


 


 


December 31,


 


 


2025


 


2024


Annualized recurring revenue


 


$


411,435


 


$


414,764


Less annualized PeopleSoft recurring revenue


 


 


15,630


 


 


30,720


Adjusted annualized recurring revenue


 


$


395,805


 


$


384,044


 


 


 


 


 


 


 


December 31, 2025


 


December 31, 2024


Remaining performance obligations


 


$


652,947


 


$


587,941


Less PeopleSoft remaining performance obligations


 


 


20,700


 


 


22,089


Adjusted remaining performance obligations


 


$


632,247


 


$


565,852


About Non-GAAP Financial Measures and Certain Key Metrics


To provide investors and others with additional information regarding Rimini Street’s results, we have disclosed the following non-GAAP financial measures and certain key metrics. We have described below Active Clients, Annualized Recurring Revenue, Adjusted Annualized Recurring Revenue and Revenue Retention Rate, each of which is a key operational metric for our business. In addition, we have disclosed the following non-GAAP financial measures: non-GAAP operating income, non-GAAP net income, EBITDA, Adjusted EBITDA, Calculated Billings, Adjusted Calculated Billings, Remaining Performance Obligations and Adjusted Remaining Performance Obligations. Rimini Street has provided in the tables above a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. There were no tax effects associated with any of our non-GAAP adjustments. These non-GAAP financial measures are also described below.


The primary purpose of using non-GAAP measures is to provide supplemental information that management believes may prove useful to investors and to enable investors to evaluate our results in the same way management does. We also present the non-GAAP financial measures because we believe they assist investors in comparing our performance across reporting periods on a consistent basis, as well as comparing our results against the results of other companies, by excluding items that we do not believe are indicative of our core operating performance. Specifically, management uses these non-GAAP measures as measures of operating performance; to prepare our annual operating budget; to allocate resources to enhance the financial performance of our business; to evaluate the effectiveness of our business strategies; to provide consistency and comparability with past financial performance; to facilitate a comparison of our results with those of other companies, many of which use similar non-GAAP financial measures to supplement their GAAP results; and in communications with our board of directors concerning our financial performance. Investors should be aware however, that not all companies define these non-GAAP measures consistently.


Active Client is a distinct entity that purchases our services to support a specific product, including a company, an educational or government institution, or a business unit of a company. For example, we count as two separate active clients when support for two different products is being provided to the same entity. We believe that our ability to expand our active clients is an indicator of the growth of our business, the success of our sales and marketing activities, and the value that our services bring to our clients.


Annualized Recurring Revenue is the amount of subscription revenue recognized during a fiscal quarter and multiplied by four. This gives us an indication of the revenue that can be earned in the following 12-month period from our existing client base, assuming no cancellations or price changes occur during that period. Subscription revenue excludes any non-recurring revenue, which has been insignificant to date.


Adjusted Annualized Recurring Revenue is annualized recurring revenue adjusted to exclude PeopleSoft subscription revenue recognized during a fiscal quarter and multiplied by four.


Revenue Retention Rate is the actual subscription revenue (dollar-based) recognized over a 12-month period from customers that were clients on the day prior to the start of such 12-month period, divided by our Annualized Recurring Revenue as of the day prior to the start of the 12-month period.


Non-GAAP Operating Income is operating income (loss) adjusted to exclude: litigation costs and related recoveries, net, stock-based compensation expense and reorganization costs. The exclusions are discussed in further detail below.


Non-GAAP Net Income is net income (loss) adjusted to exclude: litigation costs and related recoveries, net, stock-based compensation expense and reorganization costs. These exclusions are discussed in further detail below.


Specifically, management excludes the following items from its non-GAAP financial measures, as applicable, for the periods presented:


Litigation Costs and Related Recoveries, Net: Litigation costs and the associated litigation settlement, insurance and appeal recoveries relate to outside costs of litigation activities. These costs and recoveries reflect the litigation we are involved with, and do not relate to the day-to-day operations or our core business of serving our clients.


Stock-Based Compensation Expense: Our compensation strategy includes the use of stock-based compensation to attract and retain employees. This strategy is principally aimed at aligning employee interests with those of our stockholders and to achieve long-term employee retention. As a result, stock-based compensation expense varies for reasons that are generally unrelated to operational decisions in any particular period.


Reorganization Costs: The costs consist primarily of severance costs associated with the Company's reorganization plan.


EBITDA is net income (loss) adjusted to exclude: interest expense, income taxes, and depreciation and amortization expense.


Adjusted EBITDA is EBITDA adjusted to exclude: litigation costs and related recoveries, net, stock-based compensation expense and reorganization costs, as discussed above.


Calculated Billings represents the change in deferred revenue for the current period plus revenue for the current period.


Adjusted Calculated Billings is calculated billings adjusted to exclude the calculated billings associated with PeopleSoft services.


Remaining Performance Obligations represent all future non-cancellable revenue under contract that has not yet been recognized as revenue, and includes deferred revenue and unbilled amounts.


Adjusted Remaining Performance Obligations is the Company's remaining performance obligations adjusted to exclude the remaining performance obligations for PeopleSoft.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260219293814/en/



Permalink

https://aetoswire.com/en/news/2002202653440


Contacts

Investor Relations Contact

Dean Pohl

Rimini Street, Inc.

+1 925 523-7636

dpohl@riministreet.com


Media Relations Contact

Janet Ravin

Rimini Street, Inc.

+1 702 285-3532

pr@riministreet.com

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

 OSAKA, Japan & CAMBRIDGE, Mass. - Friday, 20. February 2026 AETOSWire 


Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly half (47.3%) of randomized patients achieved primary endpoint of clinical remission at 54 weeks

Vedolizumab’s safety profile was generally consistent with its known safety profile in adults

Results were presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO)

 


(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), show vedolizumab’s promising efficacy and safety profile in a patient population where therapy options remain limited. With KEPLER, Takeda is continuing to generate deeper scientific insights and identify additional patient populations who may benefit from vedolizumab, a cornerstone therapy for adults with ulcerative colitis. Vedolizumab is marketed under the trade name ENTYVIO®*.


“Ulcerative colitis is a life-altering diagnosis for young patients and their families, often leaving them searching for effective options. In the KEPLER study, we observed clinically meaningful improvements with vedolizumab in an especially difficult-to-treat patient population—children and adolescents who had failed on the current standard of care, including conventional therapies and/or tumor necrosis factor (TNF) antagonists,” said Ramalingam Arumugam, MD, study investigator and pediatric gastroenterologist at MNGI Digestive Health in Minnesota. “Study data showed nearly half of patients were in remission after one year and safety was generally consistent with vedolizumab’s profile in adults, suggesting that vedolizumab could become important in addressing pediatric UC in those 2 years of age and older.”


The KEPLER Phase 3 study included 120 children and adolescents 2 to 17 years-old with moderately to severely active UC who had an inadequate response to conventional treatments (such as steroids and immunomodulators) and/or tumor necrosis factor (TNF) antagonists. Study participants received open-label intravenous (IV) vedolizumab during a 14 week open-label induction period.1 Ninety-three (93) of 120 patients who achieved a clinical response at Week 14 were then randomized to low dose (n=47) or high dose (n=46) maintenance therapy with vedolizumab every 8 weeks. Of these 93 patients:


Nearly half (47.3%) of participants achieved the primary endpoint of clinical remission at Week 54;

More than one-third (34.7%) of patients achieved clinical remission at 14 weeks (secondary endpoint); and

Greater than 1 in 4 (29%) participants attained the secondary endpoint of sustained clinical remission at both Weeks 14 and 54.

Additionally, the safety profile of vedolizumab in trial participants was generally consistent with its established safety profile in adults, with no new safety signals identified.1 The most frequently occurring treatment-emergent adverse events (≥10%) reported with vedolizumab in the KEPLER study were upper respiratory infection (30%), ulcerative colitis (disease worsening) (17.5%), and pyrexia (12.5%).3

“For too long, families and clinicians caring for children and adolescents with ulcerative colitis have had limited therapeutic options,” said Awny Farajallah, MD, chief medical officer of Takeda. “The Phase 3 KEPLER results are encouraging and suggest that ENTYVIO, a therapy with a well-established role in the treatment of ulcerative colitis, may offer a meaningful benefit for patients as young as two years old. These findings build on more than a decade of scientific study demonstrating the safety and efficacy of ENTYVIO and reflect Takeda’s continued leadership in advancing evidence-based care across the full spectrum of inflammatory bowel disease. Importantly, this study underscores our commitment to supporting some of the most vulnerable patient populations in gastroenterology.”


Takeda plans to submit marketing applications in the United States, the European Union and other markets for intravenous ENTYVIO for the treatment of moderately to severely active ulcerative colitis in children and adolescents ages 2-17.


About the Phase 3 KEPLER Study

KEPLER (NCT 04779307; EudraCT 2020-004300-34) is a Phase 3, global, randomized, double-blind, multi-center study to evaluate the efficacy and safety of vedolizumab IV in patients ages 2 to 17 with moderately to severely active ulcerative colitis (modified Mayo score of 5-9 with endoscopic subscore ≥2) with inadequate response to conventional therapy, such as steroids, immunomodulators, and/or tumor necrosis factor (TNF) antagonists.4,1 The study included a 14-week open-label induction period—all participants received IV vedolizumab—followed by a 40-week, randomized, double-blind maintenance period comparing two dose levels: low dose (LD) and high dose (HD). Ninety-three (93) participants were randomized to LD (n=47) or HD (n=46) arms, according to patient weight:


Participants ≥30 kg: vedolizumab 300 mg (HD) or 150 mg (LD)

Participants >15 to <30 kg: vedolizumab 200 mg (HD) or 100 mg (LD)

Participants 10 to 15 kg: vedolizumab 150 mg (HD) or 100 mg (LD)

The primary endpoint was clinical remission at Week 54 in patients who achieved clinical response following open-label vedolizumab IV induction, defined here by symptomatic improvement and endoscopic evidence of no or minimal disease activity (modified Mayo Score).4 Secondary outcome measures included safety and tolerability across induction and maintenance, sustained clinical remission (clinical remission at Weeks 14 and 54), endoscopic outcomes, the impact of dose escalation for loss of response, and long-term safety and disease control assessed in follow-up periods.


About ENTYVIO® (vedolizumab)

Vedolizumab is the only gut-selective biologic therapy available for ulcerative colitis and Crohn’s disease. It specifically binds to the alpha4beta7 integrin and blocks its interaction with MAdCAM-1, which is mainly expressed on the gut endothelial cells.5 Vedolizumab is approved for IV and subcutaneous (SC) administration in adults with moderately to severely active ulcerative colitis and Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist (approvals vary by market).6,7 Vedolizumab IV has been granted marketing authorization in more than 80 countries, including the United States and European Union. Vedolizumab SC has been granted marketing authorization in more than 50 countries, including the United States and European Union. Globally, vedolizumab IV and SC have more than one million patient years of exposure to date.3


*In most markets worldwide.


EUROPEAN UNION IMPORTANT SAFETY INFORMATION


Please consult the ENTYVIO (Vedolizumab) Summary of Product Characteristics (SmPC) before prescribing, particularly in relation to dosing and treatment monitoring.


GUIDANCE FOR USE: Entyvio should be initiated and supervised by a specialist healthcare professional experienced in diagnosis and treatment of ulcerative colitis, Crohn’s disease or pouchitis. Patients should be given the package leaflet.


CONTRAINDICATIONS: include Hypersensitivity to the active substance or to any of the excipients. Active severe infections such as tuberculosis (TB), sepsis, cytomegalovirus, listeriosis, and opportunistic infections such as Progressive Multifocal Leukoencephalopathy (PML).


UNDESIRABLE EFFECTS: The most commonly reported undesirable effects with ENTYVIO are nasopharyngitis, headache, arthralgia, pneumonia, Clostridium difficile infection, bronchitis, gastroenteritis, upper respiratory tract infection, influenza, sinusitis, pharyngitis, Herpes Zoster, paraesthesia, hypertension, oropharyngeal pain, nasal congestion, cough, anal abscess, anal fissure, nausea, dyspepsia, constipation, abdominal distension, flatulence, haemorrhoids, rectal haemorrhage, liver enzyme increased, rash, pruritus, eczema, erythema, night sweats, acne, muscle spasms, back pain, muscular weakness, fatigue, pain in the extremity, pyrexia, infusion related reaction, infusion site reaction and injection site reaction (subcutaneous administration only).


No clinically relevant differences in the overall safety profile and adverse reactions were observed in patients who received subcutaneous vedolizumab compared to the safety profile observed in clinical studies with intravenous vedolizumab with the exception of injection site reactions (with subcutaneous administration).


Please click for the full EU SmPC.


U.S. IMPORTANT SAFETY INFORMATION 


CONTRAINDICATIONS

ENTYVIO is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients. 


WARNINGS AND PRECAUTIONS 


Infusion-Related and Hypersensitivity Reactions: Infusion-related reactions and hypersensitivity reactions including anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have been reported. These reactions may occur with the first or subsequent infusions and may vary in their time of onset from during infusion or up to several hours post-infusion. If anaphylaxis or other serious infusion-related or hypersensitivity reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.

Infections: Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice.

Progressive Multifocal Leukoencephalopathy (PML): PML, a rare and often fatal opportunistic infection of the central nervous system (CNS), has been reported with systemic immunosuppressants, including another integrin receptor antagonist. PML typically only occurs in patients who are immunocompromised. One case of PML in an ENTYVIO-treated patient with multiple contributory factors has been reported. Although unlikely, a risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms that may include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to neurologist; if confirmed, discontinue ENTYVIO dosing permanently.

Liver Injury: There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.

Live and Oral Vaccines: Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines. Patients receiving ENTYVIO may receive non-live vaccines and may receive live vaccines if the benefits outweigh the risks.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥3% and ≥1% higher than placebo) were: nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities, and injection site reactions with subcutaneous administration.


DRUG INTERACTIONS

Because of the potential for increased risk of PML and other infections, avoid the concomitant use of ENTYVIO with natalizumab products and with TNF blockers. Upon initiation or discontinuation of ENTYVIO in patients treated with CYP450 substrates, monitor drug concentrations or other therapeutic parameters, and adjust the dosage of the CYP substrate as needed. 


INDICATIONS

Adult Ulcerative Colitis (UC):

ENTYVIO is indicated in adults for the treatment of moderately to severely active UC. 


Adult Crohn’s Disease (CD):

ENTYVIO is indicated in adults for the treatment of moderately to severely active CD. 


DOSAGE FORMS & STRENGTHS: 


ENTYVIO Intravenous (IV) Infusion: 300 mg vedolizumab 

ENTYVIO Subcutaneous (SC) Injection: 108 mg vedolizumab

Please click for Full U.S. Prescribing Information.


About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.


Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.


The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.


Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.


Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.


References


1 Turner D, Kierkuś J, Korczowski B, Strisciuglio C, Chen J, Takaki Y, et al. J Crohns Colitis. 2026 Jan 1;20(Supplement_1):i181-183.

2 Vuijk SA, et al. J Crohns Colitis. 2024;18(Supplement_2):ii31-ii45.

3 Data on file. Takeda Pharmaceuticals.

4 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC).

ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04779307. Last accessed January 20, 2026.

5 Soler D, Chapman T, Yang LL, et al. J Pharmacol Exp Ther. 2009;330(3):864-875.

6 ENTYVIO (vedolizumab) Prescribing Information. Takeda Pharmaceuticals. Available at: https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1.

7 ENTYVIO Summary of Product Characteristics (SmPC). Takeda Pharmaceuticals. Available at: https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_en.pdf.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260218745615/en/



Permalink

https://www.aetoswire.com/en/news/2002202653438


Contacts

Media Contacts:

Takeda Media Relations

media_relations@takeda.com

Friday, February 20, 2026

iCAUR V27 Makes Its First Global Launch In The UAE

 iCAUR officially launches, positioning the UAE as a key global strategic market

The brand targets young and young-at-heart consumers.

The V27 redefines the classic SUV with timeless design and dynamic performance, wrapped in cutting-edge technology.

 


iCAUR, a leading hybrid and electric vehicle brand making waves worldwide, has now officially arrived in the UAE. The brand was launched at a glamorous gala evening at the Park Hyatt Dubai, attended by senior global executives from iCAUR, VIP guest,s and respected members of the media.


As part of the classical theme experience, guests were invited to explore the design and engineering philosophy behind the V27. The showcase highlighted key elements of the vehicle, offering an inside look at how the V27 was conceived, designed, and brought to life, from its distinctive exterior form and interior detailing to the advanced technology that powers its performance. This immersive display allowed visitors to understand not just what the V27 is, but why it was created.


Spearheading the brand’s launch in the Middle East is iCAUR’s mid-to-large all-round hybrid SUV, the iCAUR V27, which enjoyed its global launch in Dubai. This marks the official announcement of its availability to customers worldwide, after the model already drew attention at multiple major global automotive events over the past year.


Tim Zhang, General Manager of Chery International Middle East, said at the launch: "iCAUR’s global debut in the UAE reflects our commitment to consumers across the Middle East. We are dedicated to delivering leading products and premium experiences to young and young-at-heart customers in the region."


True to iCAUR’s vision of a new-energy classic, the V27 blends quintessential boxy SUV design with pioneering New Energy technology to deliver a versatile, rugged SUV experience, both in the city and off-road.


As the brand’s flagship release of the year, the V27 has been developed and tested to exceed industry standards in every way. Before its official launch, the iCAUR development team conducted rigorous road testing in the UAE and Saudi Arabia, including extreme summer heat trials and high-speed intercity driving, ensuring the V27 is fully prepared to confidently handle diverse real-world conditions.


During development, more than 1,000 test vehicles were deployed to multiple locations worldwide, completing over 50 comprehensive test programmes. The total durability testing mileage exceeded 1 million kilometres, covering extreme heat, severe cold, and complex road conditions. This full-cycle, multi-scenario validation ensures that the V27 is fully prepared as it enters the market.


On the product side, the V27 adopts a classic design philosophy. At more than five metres long, its boxy profile is paired with classic round headlights and refined surfaces, striking a balance between rugged character and technological aesthetics.


Inside, the “Stellar Cockpit” concept features the class-first Stellar Porthole dual panoramic sun screen with 99.9% UV blockage, and the floating Star Island ceiling, creating a spacious and tech-forward cabin experience. With a 2,900mm wheelbase and efficient use of space, it offers a roomy and comfortable five-seat layout.


In terms of power, the Golden REEV (Range-Extended Electric Vehicle) provides over 150km pure electric range and more than 995km combined range, while balancing performance and efficiency to meet urban, long-distance, and multi-scenario driving needs.


Unlike conventional plug-in hybrids, the REEV system is fully driven by electric motors, delivering instant torque and smooth acceleration, while the gasoline engine functions solely as a generator when required.


Excitingly, iCAUR continues to build its ecosystem of customisations. The V27 comes with 39 pre-installed ecosystem ports and offers a wide range of upgrade accessories to enhance users’ high-quality lifestyle.


UAE customers will be supported with a network of showrooms and service centres. iCAUR has already opened the flagship showroom at Dubai’s Oasis Centre on Sheikh Zayed Road, along with showrooms in Abu Dhabi and Sharjah. These three strategic locations form the basis of iCAUR’s ambitious plans to expand the dealership and distribution network across all seven emirates. 


In addition, as an important member of the iCAUR ecosystem, the AiMOGA Robots will be showcased alongside the V27 in showrooms, allowing users to experience the cutting-edge technology of the new energy era firsthand.


“We have a clear vision for the UAE market – we are not content to simply open showrooms – these locations will be part of a bigger eco-system that includes world class after-sales service and establishing dedicated owner communities, so our valued customers can share experiences, enjoy interesting drives, interact with our highly trained teams and make new friends,” Mr Zhang commented.


Following its global launch in Dubai, the V27 is set to arrive in more countries and regions throughout the year, offering users worldwide a new choice of classic, new-energy boxy SUVs.


For more information on the iCAUR V27, visit www.icauruae.com.



Permalink

https://aetoswire.com/en/news/2002202653454


Contacts

Namita Thakkar - namita@matrixdubai.com